Convection-enhanced delivery for the treatment of glioblastoma

Neuro-Oncology

Volumn 17, Issue , 2015, Pages ii3-ii8

  Vogelbaum, Michael A ^a   Aghi, Manish K ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

blood brain barrier; CED infusates; convection enhanced delivery (CED); delivery vehicles; glioblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CITREDEKIN BESUDOTOX; CONTRAST MEDIUM; FERRIC OXIDE; LIPOSOME; MAGNETIC NANOPARTICLE; METHOTREXATE; MONOCLONAL ANTIBODY; NANOPARTICLE; NITROSOUREA DERIVATIVE; OLIGONUCLEOTIDE; PSEUDOMONAS EXOTOXIN; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CATHETER; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONVECTION ENHANCED DELIVERY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG SAFETY; EQUIPMENT DESIGN; EXTERNAL BEAM RADIOTHERAPY; FLOW RATE; GLIOBLASTOMA; HUMAN; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PONTINE GLIOMA; REVIEW; SURGICAL NAVIGATION SYSTEM; SURVIVAL RATE; VIRUS PARTICLE; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); INFUSION PUMP; THERMODYNAMICS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CATHETERS; CLINICAL TRIALS AS TOPIC; CONVECTION; GLIOBLASTOMA; HUMANS; INFUSION PUMPS, IMPLANTABLE; TREATMENT OUTCOME;

EID: 84924536171     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou354     Document Type: Review

References (53)

1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(Suppl 2): ii1-i56.
2. Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg. 2014;120(4):846-853.
3. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992; 34(6):463-469.
4. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25(16):2295-2305.
5. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12(8):871-881.
6. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65(1):3-13.
7. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. 2003;64(1-2): 125-137.
8. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl. 2003;88:93-103.
9. Wersall P, Ohlsson I, Biberfeld P, et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermalgrowth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother. 1997;44(3):157-164.
10. Brem H, Mahaley MS Jr., Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991;74(3):441-446.
11. Pollina J, Plunkett RJ, Ciesielski MJ, et al. Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. J Neurooncol. 1998;39(3):217-225.
12. Boiardi A, Silvani A, Pozzi A, et al. Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. J Neurooncol. 1999;41(2):151-157.
13. Nierenberg D, Harbaugh R, Maurer LH, et al. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery. 1991;28(5):752-761.
14. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076-2080.
15. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61(4):633-641.
16. Walter KA, Tamargo RJ, Olivi A, et al. Intratumoral chemotherapy. Neurosurgery. 1995;37(6):1128-1145.
17. Bidros D, Vogelbaum MA. Barriers to delivery of therapeutics to brain tumors. In: Winn RH, ed. Youman's Neurological Surgery. 6th ed. Philadelphia: Elsevier Saunders; 2011:1172-1178.
18. Varenika V, Dickinson P, Bringas J, et al. Detection of infusate leakage in the brain using real-time imaging of convectionenhanced delivery. J Neurosurg. 2008;109(5):874-880.
19. Lonser RR, Gogate N, Morrison PF, et al. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg. 1998;89(4): 616-622.
20. Anderson RC, Kennedy B, Yanes CL, et al. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr. 2013;11(3):289-295.
21. Lonser RR, Schiffman R, Robison RA, et al. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology. 2007;68(4):254-261.
22. Shahar T, Ram Z, Kanner AA. Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls. J Neurooncol. 2012;107(2):373-378.
23. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002;97(4):905-913.
24. Chen PY, Ozawa T, Drummond DC, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013;15(2):189-197.
25. Hall WA, Sherr GT. Convection-enhanced delivery: targeted toxin treatment of malignant glioma. Neurosurg Focus. 2006;20(4):E10.
26. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994; 271(1):58-65.
27. Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol. 2007;83(1):97-109.
28. Geer CP, Grossman SA. Interstitial fluid flow along white matter tracts: a potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol. 1997;32(3):193-201.
29. Yang X, Saito R, Nakamura T, et al. Peri-tumoral leakage during intra-tumoral convection-enhanced delivery has implications for efficacy of peri-tumoral infusion before removal of tumor. Drug Deliv. 2014;0:1-6.
30. Guarnieri M, Carson BS, Khan A, et al. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J Neurosci Methods. 2005;144(2): 147-152.
31. Stukel JM, Caplan MR. Targeted drug delivery for treatment and imaging of glioblastoma multiforme. Expert Opin Drug Deliv. 2009;6(7):705-718.
32. Sampson JH, Brady M, Raghavan R, et al. Colocalization of gadolinium-diethylene triamine pentaacetic acid with highmolecular-weight molecules after intracerebral convectionenhanced delivery in humans. Neurosurgery. 2011;69(3):668-676.
33. Linninger AA, Somayaji MR, Mekarski M, et al. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol. 2008;250(1):125-138.
34. Bruce JN, Fine RL, Canoll P, et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 2011;69(6):1272-1279; discussion 1279-1280.
35. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3(12):1362-1368.
36. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery. 2005;56(6):1243-1252. discussion 1252-1243.
37. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132-142.
38. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54(4):479-487.
39. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convectionenhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 2007;61(5):1031-1037. discussion 1037-1038.
40. White E, Bienemann A, Pugh J, et al. An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma. J Neurooncol. 2012;108(1):77-88.
41. Barua NU, Woolley M, Bienemann AS, et al. Convection-enhanced delivery of AAV2 in white matter-a novel method for gene delivery to cerebral cortex. J Neurosci Methods. 2013;220(1):1-8.
42. Carpentier A, Metellus P, Ursu R, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol. 2010;12(4):401-408.
43. Bernal GM, LaRiviere MJ, Mansour N, et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2014;10(1): 149-157.
44. Corem-Salkmon E, Ram Z, Daniels D, et al. Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine. 2011;6:1595-1602.
45. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70(15): 6303-6312.
46. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1(1):34-42.
47. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg. 2008;108(5):989-998.
48. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 2005;1035(2):139-153.
49. Rosca EV, Stukel JM, Gillies RJ, et al. Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules. 2007;8(12):3830-3835.
50. Murad GJ, Walbridge S, Morrison PF, et al. Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg. 2007;106(2):351-356.
51. Fiandaca MS, Varenika V, Eberling J, et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage. 2009;47(Suppl 2):T27-T35.
52. Rosenbluth KH, Martin AJ, Mittermeyer S, et al. Rapid inverse planning for pressure-driven drug infusions in the brain. PLoS One. 2013;8(2):e56397.
53. Sonabend AM, Stuart RM, Yun J, et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol. 2011;13(8):886-893.